Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 948 • 2016 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety
DJ Lovell¹, N Ruperto², N Tzaribachev³, G Vega-Cornejo⁴, I Louw⁵, A Berman^6,7, I Calvo⁸, R Cuttica⁹, G Horneff¹⁰, F Avila-Zapata¹¹, J Anton¹², R Cimaz¹³, E Solau-Gervais¹⁴, R Joos¹⁵, G Espada¹⁶, X Li¹⁷, M Nys¹⁸, R Wong¹⁷, S Banerjee¹⁷, Hermine I. Brunner¹⁹, A Martini²⁰ and For Pediatric Rheumatology International Trials Organization (PRINTO)/Pediatric Rheumatology Collaborative Study Group (PRCSG), ¹Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Istituto G. Gaslini Pediatria II Reumatologia, Genoa, Italy, ³Pediatric Rheumatology, Bad Bramstedt, Germany, ⁴Clinica de Rheumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, ⁵Panorama Medical Centre, Cape Town, South Africa, ⁶Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁷Universidad Nacional de Tucuman and Centro Médico Privado de Reumatología, Tucuman, Argentina, ⁸Hospital Univ. La Fe, Valencia, Spain, ⁹Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ¹⁰Centre Paediatric Rheumatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ¹¹Star Medica Hospital, Merida, Mexico, ¹²Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ¹³Pediatrics, Ospedale Pediatrico Anna Meyer, Florence, Italy, ¹⁴Hôpital de la Miletrie, Poitiers, France, ¹⁵University Hospital Gent, Gent, Belgium, ¹⁶Cramer 1853 4°C, Hospital de Ninos Dr Ricardo Gutierrez, Buenos Aires, Argentina, ¹⁷Bristol-Myers Squibb, Princeton, NJ, ¹⁸Bristol-Myers Squibb, Braine-l’Alleud, Belgium, ¹⁹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁰Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genoa, Italy
Background/Purpose: IV abatacept (ABA) 10 mg/kg every 4 weeks was well tolerated and effective in reducing the signs and symptoms of polyarticular-course juvenile idiopathic arthritis…
Abstract Number: 335 • 2016 ACR/ARHP Annual Meeting
High Risk of Osteoporosis and Long Term Joint Damage in Adults with a History of Juvenile Idiopathic Arthritis
Hiranda Dodanwala¹, Danielle Feger¹, Nicholas Longson², Nancy J. Olsen³, Barbara E. Ostrov^4,5 and Rayford R. June⁶, ¹Medicine - Division of Rheumatology, Penn State Milton S. Hershey Medical Center, Hershey, PA, ²Johns Hopkins University, Baltimore, MD, ³Divsion of Rheumatology, Department of Medicine, Penn State MS Hershey Medical Center, Hershey, PA, ⁴Pediatrics, Penn State Hershey Medical Center, Hershey, PA, ⁵Pediatrics, Penn State Hershey Children's Hospital, Hershey, PA, ⁶Rheumatology, Penn State Hershey Medical Center, Hershey, PA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a heterogeneous group of chronic inflammatory arthritides. JIA is the most common cause of musculoskeletal disability in children, and…
Abstract Number: 949 • 2016 ACR/ARHP Annual Meeting
Comparison of Treatment Response, Remission Rate and Drug Adherence in Polyarticular Juvenile Idiopathic Arthritis Patients Treated with Etanercept, Adalimumab or Tocilizumab
Gerd Horneff^1,2, Ariane Klein³, Kirsten Minden^4,5, Hans-Iko Huppertz⁶, Frank Weller-Heinemann⁷, Jasmin B. Kuemmerle-Deschner⁸, Johannes Peter Haas⁹ and Toni Hospach¹⁰, ¹Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ²Department of Pediatrics, Centre of Pediatric Rheumatology, Sankt Augustin, Germany, ³Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁴Epidemiology, Charite, DRFZ, Berlin, Germany, ⁵Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁶Klinikum Bremen-Mitte, Prof.-Hess-Kinderklinik, Bremen, Germany, ⁷Prof.-Hess-Kinderklinik, Bremen,, Berlin, Germany, ⁸Universitätsklinikum Tübingen, Klinik fuer Kinder- und Jugendmedizin, Tübingen, Germany, ⁹German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ¹⁰Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany
Background/Purpose: Treatment response, remission rates and compliance in polyarticular JIA patients treated with adalimumab(ADA), etanercept(ETA), or tocilizumab(TCZ) were analyzed in clinical practice. Methods: Data from the German BIKER…
Abstract Number: 376 • 2016 ACR/ARHP Annual Meeting
Initial Validation of the Patient Reported Outcomes Measurement Information System Pediatric Pain Intensity Scale in Juvenile Idiopathic Arthritis, Juvenile Fibromyalgia and Sickle Cell Disease
Esi Morgan¹, Constance Mara², Bin Huang³, Adam Carle⁴, Kenneth Goldschneider⁵, Carlton Dampier⁶ and Susmita Kashikar-Zuck⁷, ¹Pediatric Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ²James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Anesthesia, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Department of Pediatrics (Hematology-Oncology), Emory University School of Medicine, Atlanta, GA, ⁷Behavioral Medicine & Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The Patient Reported Outcomes Measurement Information System(PROMIS) is a publicly available assessment system offering multiple measures to assess physical, mental and social health.…
Abstract Number: 1240 • 2016 ACR/ARHP Annual Meeting
A Minority of Patients Utilize Most of Healthcare Resources in Rheumatoid Arthritis, Psoriatic Arthritis, Juvenile Idiopathic Arthritis, and Axial Spondyloarthritis
Nina Mars¹, Anne M Kerola², Markku J Kauppi^3,4, Outi Elonheimo^5,6, Santeri Huvinen^5,6 and Tuulikki Sokka-Isler^7,8, ¹University of Helsinki, Helsinki, Finland, ²Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ³School of Medicine, University of Tampere, Tampere, Finland, ⁴Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁵Network of Academic Health Centres, Department of Medicine, University of Helsinki, Helsinki, Finland, ⁶FCG Finnish Consulting Group Ltd., Helsinki, Finland, ⁷Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁸RAID working group for EULAR, Zurich, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) is associated with high healthcare costs, but little is known about how the costs compare to other chronic rheumatic diseases. We…
Abstract Number: 387 • 2016 ACR/ARHP Annual Meeting
Rituximab Should be Considered in Rheumatoid Factor Negative Poly-Articular Juvenile Idiopathic Arthritis
Sunil Sampath^1,2, Liza J. McCann³, Michael W. Beresford^3,4, Eileen Baildam³, Jamie C Sergeant^1,5, Wendy Thomson², Helen Foster⁶, Sharon Douglas², Taunton Southwood⁷, Kimme L. Hyrich¹ and Biologics for Children with Rheumatic Diseases (BCRD) study Group¹, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ³Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ⁴Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, ⁵NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁶Paediatric Rheumatology, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom, ⁷School of Immunity and Infection,Institute of Clinical Sciences,University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Selective peripheral B-cell depletion by rituximab (RTX) is a relatively recent advance in rheumatic diseases. RTX is an approved treatment in RA. Although very…
Abstract Number: 1289 • 2016 ACR/ARHP Annual Meeting
Comparison of Clinical Parameters and PET/MRI in Juvenile Idiopathic Arthritis
Kathleen Jo Corbin¹, Emily von Scheven¹, Youngho Seo², Spencer Behr² and John MacKenzie³, ¹Division of Rheumatology, Department of Pediatrics, University of California, San Francisco, San Francisco, CA, ²Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA, ³Section of Pediatric Radiology, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA
Background/Purpose: Positron emission tomography (PET) can be used to identify inflammation using 18F-fluorodeoxyglucose (18F-FDG). 18F-FDG uptake correlates with clinical and laboratory markers of disease activity…
Abstract Number: 388 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Two to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis
Hermine I. Brunner¹, Nicolino Ruperto², Anasuya Hazra³, Ronnie Wang⁴, Charles Mebus⁴, Christine Alvey⁴, Manisha Lamba⁴, Sriram Krishnaswami⁴, Thomas C Stock³, Umberto Conte⁵, Min Wang⁵, Nikolay Tzaribachev⁶, Ivan Foeldvari⁷, Gerd Horneff⁸, Daniel Kingsbury⁹, Elena Koskova¹⁰, Elzbieta Smolewska¹¹, Richard K Vehe¹², Zbigniew Zuber¹³, Daniel J Lovell¹ and Alberto Martini², ¹Pediatric Rheumatology Collaborative Study Group, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Istituto Giannina Gaslini, Genoa, Italy, ³Pfizer Inc, Collegeville, PA, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶Pediatric Rheumatology Research Institute, Bad Bramstedt, Bad Bramstedt, Germany, ⁷Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg, Germany, ⁸Asklepios Klinik, Sankt Augustin, Germany, ⁹Randall Children's Hospital, Portland, OR, ¹⁰National Institute of Rheumatic Diseases, Piestany, Piestany, Slovakia, ¹¹Department of Pediatric Cardiology and Rheumatology, Medical University of Lodz, Lodz, Poland, ¹²University of Minnesota Masonic Children’s Hospital, Minneapolis, MN, ¹³St Louis Children’s Hospital ODS Rheumatology and Neurology, Krakow, Poland
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor that is being investigated for juvenile idiopathic arthritis (JIA). Here, we report the pharmacokinetics (PK), safety, and…
Abstract Number: 1517 • 2016 ACR/ARHP Annual Meeting
Does Inflammatory Arthritis Really Improve during Pregnancy? a Systematic Review and Meta-Analysis
Hannah Jethwa¹, Suzanne Lam², Colette Smith³ and Ian Giles⁴, ¹General Medicine, Wexham Park Hospital, London, United Kingdom, ²Croyden University Hospital, London, United Kingdom, ³Statistics, Royal Free Hospital Foundation Trust, London, United Kingdom, ⁴Centre for Rheumatology, University College London, Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Disease activity is considered to improve in approximately 75% of patients with rheumatoid arthritis (RA) during pregnancy. This figure, however, is derived from…
Abstract Number: 392 • 2016 ACR/ARHP Annual Meeting
Safety and Clinical Response of Weekly Adalimumab in the Treatment of Juvenile Idiopathic Arthritis, Pediatric Chronic Uveitis and Other Childhood Rheumatic Diseases
Colleen K. Correll¹, Danielle R. Bullock¹, Rachel Cafferty¹ and Richard K Vehe², ¹Pediatrics, University of Minnesota, Minneapolis, MN, ²University of Minnesota Masonic Children’s Hospital, Minneapolis, MN
Background/Purpose: Every other week adalimumab is used to treat juvenile idiopathic arthritis (JIA) and other pediatric rheumatic diseases. It is common for pediatric rheumatologists to…
Abstract Number: 2038 • 2016 ACR/ARHP Annual Meeting
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Improvement on Quality Measures for Children with Juvenile Idiopathic Arthritis
C. April Bingham¹, Jesse Pratt², Cagri Yildirim-Toruner³, Ronald Laxer⁴, Beth Gottlieb⁵, Jennifer E. Weiss⁶, Tzielan Lee⁷, Sheetal S. Vora⁸, Jon M. Burnham⁹, Julia Harris¹⁰, Judyann C. Olson¹¹, Murray Passo¹², Michelle Batthish¹³, Michael Shishov¹⁴, Kerry Ferraro¹⁵, Deborah M. Levy¹⁶, Christine O'Brien¹⁷, Kristi Whitney-Mahoney¹⁷, Nancy Griffin¹⁸, Anne Paul¹⁹ and Esi Morgan²⁰, ¹Penn State Health Children's Hospital, Hershey, PA, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Rheumatology, Nationwide Children's Hospital, Columbus, OH, ⁴Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Pediatrics, Cohen Children's Medical Center, Lake Success, NY, ⁶Hackensack Univ Med Ctr, Hackensack, NJ, ⁷Pediatric Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁸Pediatric Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁹Pediatric Rheumatology, Children's Hospital Philadelphia, Philadelphia, PA, ¹⁰Children's Mercy Kansas City, Kansas City, MO, ¹¹Ped/MACC Fund Research Ctr, Medical College of Wisconsin, Milwaukee, WI, ¹²Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ¹³Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ¹⁴Pediatric Rheumatology, Phoenix Children's Hospital, Phoenix, AZ, ¹⁵Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ¹⁶Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁷The Hospital for Sick Children, Toronto, ON, Canada, ¹⁸James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁹Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²⁰Pediatric Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a growing multi-center network organized on a learning health system model designed to improve outcomes…
Abstract Number: 395 • 2016 ACR/ARHP Annual Meeting
The Influence of Early Achievement of “Clinically Inactive Disease” or “Minimal Disease Activity” on Long-Term Disability Outcomes in JIA
Stephanie J.W.Shoop^1,2, Suzanne M.M. Verstappen³, Janet E. McDonagh⁴, Wendy Thomson^5,6, Kimme L. Hyrich^3,7 and CAPS, ¹Central Manchester University Hospitals NHS Foundation Trust and University of Manchester Partnership, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, ²The University of Manchester, Arthritis Research UK Centre for Epidemiology, Manchester, United Kingdom, ³Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁴Faculty of Medical and Human Sciences, Centre for MSK Research, Manchester, United Kingdom, ⁵Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom, ⁶NIHR Manchester Musculoskeletal Biomedical Research Unit, Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ⁷Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Different definitions of clinically inactive disease (CID) for JIA have recently been shown to identify different groups of children. It is unclear whether long-term…
Abstract Number: 2039 • 2016 ACR/ARHP Annual Meeting
Assessing Barriers to Uveitis Screening in Patients with JIA: A Qualitative Study
Laura Ballenger¹, Kyla Driest² and Stacy P. Ardoin³, ¹Nationwide Children's Hospital, Columbus, OH, ²Rheumatology, Nationwide Children's Hospital, Columbus, OH, ³Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH
Background/Purpose: Uveitis is a major complication in patients with juvenile idiopathic arthritis (JIA) can be completely asymptomatic until vision loss develops. In order to prevent ocular…
Abstract Number: 398 • 2016 ACR/ARHP Annual Meeting
Predictors of Clinical Remission with Etanercept in Pediatric Patients with Extended Oligoarticular, Enthesitis-Related Arthritis and Psoriatic Arthritis: Findings from the Clipper Study
Nicolino Ruperto¹, Alessandro Consolaro², Gerd Horneff¹, Rubén Burgos-Vargas¹, Tamas Constantin¹, Ivan Foeldvari¹, Jelena Vojinovic¹, Joke Dehoorne¹, Violeta Vladislava Panaviene¹, Gordana Susic¹, Valda Stanevicha¹, Katarzyna Kobusinska¹, Zbigniew Zuber³, Richard Mouy¹, Ingrida Rumba-Rozenfelde¹, Pavla Dolezalová¹, Chantal Job-deslandre⁴, Nico M Wulffraat¹, Ronald Pedersen⁵, Jack F Bukowski⁶, Tina Hinnershitz⁷, Bonnie Vlahos⁸ and Alberto Martini⁹, ¹Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ²Istituto Giannina Gaslini, Genoa, Italy, ³St Louis Children’s Hospital ODS Rheumatology and Neurology, Krakow, Poland, ⁴Pediatria II, Reumatologia, PRINTO, Istituto Giannina Gaslini, Genoa, Italy, ⁵Department of Biostatistics, Pfizer, Collegeville, PA, ⁶Clinical Affairs, Pfizer, Collegeville, PA, ⁷Specialty Care MDG, Pfizer, Collegeville, PA, ⁸GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ⁹PRINTO-IRCCS, Genoa, Italy
Background/Purpose: Etanercept (ETN) is approved in the EU for the treatment of children with juvenile idiopathic arthritis (JIA) categories of polyarticular, extended oligoarticular (eoJIA), enthesitis-related…
Abstract Number: 2408 • 2016 ACR/ARHP Annual Meeting
Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88
Keith A. Sikora¹, Joshua R. Bennett¹, Zuoming Deng², Wanxia Li Tsai³, April Brundidge³, Fatemeh Navid³, Gerlinde Layh-Schmitt³, Eric Hanson³, Massimo G. Gadina⁴, Louis M. Staudt⁵, Thomas A. Griffin⁶ and Robert A. Colbert³, ¹Pediatric Translational Research Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Biodata Mining & Discovery, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴Translational Immunology Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵National Cancer Institute, National Institutes of Health, Bethesda, MD, ⁶Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC
Background/Purpose: Myeloid differentiation primary response 88 (MyD88) is a critical adaptor protein that connects Toll-like and IL-1 receptor signaling to activation of NF-κB. Germline loss-of-function…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].